Intermediate

Heart Failure Life Expectancy Calculator

Understand statistical survival estimates for heart failure by entering age, NYHA functional class, and ejection fraction category. Results reflect population-level medians from published cohort studies — for educational reference only.

years

NYHA functional class

Ejection fraction (EF) category

Estimated median survival
6years

Population median — half survive longer, half shorter

Approx. 1-year survival (NYHA class)
90 %
Approx. 5-year survival (NYHA class)
50 %
Expected age at median endpoint
74 years
Data source
CHARM / Cowie 2000 / Shah 2017
DiagnosisMedian endpoint6 yearsEstimated median survival from diagnosis (population estimate)
Step by step
  1. 1

    NYHA class baseline median

    6
    Population median survival (years) for NYHA II at age 65–74, from CHARM / Cowie 2000 cohorts.
  2. 2

    Age + EF adjustments

    0 + 0 = 0
  3. 3

    Estimated median survival

    6 + (0) = 6
Results are estimates for general information only and are not professional advice — always verify important results independently before relying on them. This is not medical, health or fitness advice; consult a qualified healthcare professional. Read the full disclaimer.
Quick answer

How does this calculator work?

Heart failure median survival ranges from roughly 9 years (NYHA I, younger patients) to under 1 year (NYHA IV, elderly). NYHA functional class is the strongest simple predictor; ejection fraction and age also matter. Modern guideline therapies improve outcomes substantially. These are population medians from CHARM / Cowie 2000 cohorts — always consult a cardiologist for individual prognosis.

Formula
Median survival ≈ NYHA-class baseline + age adjustment + ejection-fraction adjustment (cohort data: CHARM, Cowie 2000, Shah 2017)
How this is calculated

Heart failure (HF) prognosis has improved significantly over the past 30 years with angiotensin blockers, beta-blockers, mineralocorticoid antagonists, SGLT2 inhibitors, and device therapies, but it remains a serious condition. The New York Heart Association (NYHA) functional classification — ranging from Class I (no symptoms at rest or ordinary activity) to Class IV (symptoms at rest) — is one of the strongest independent predictors of outcome in clinical studies.

This calculator applies NYHA-class survival medians derived from the CHARM clinical programme and community-based cohorts (Cowie et al. 2000 Hillingdon study; Roger et al. Olmsted County data), with an age adjustment that reflects younger patients' substantially better prognosis, and a small ejection-fraction adjustment: patients with preserved EF (HFpEF, ≥50%) have broadly similar overall mortality to HFrEF at the population level in modern cohorts, while mildly reduced EF (40–49%) occupies an intermediate position per Shah et al. 2017.

Important caveats: the estimates here are unadjusted for comorbidities (diabetes, CKD, atrial fibrillation), whether the patient receives guideline-directed therapy (which can extend survival by several years), device therapy (ICD, CRT), or the specific aetiology of HF. They reflect outcomes averaged over populations that span the pre-SGLT2 era. Individual prognosis should always be assessed by a cardiologist.

Frequently asked questions

Median survival from diagnosis varies widely: NYHA Class I–II patients often live 5–10 years or more, while Class III–IV patients may have a median survival of 1–3 years without aggressive intervention. Modern therapies including SGLT2 inhibitors and cardiac resynchronisation therapy have meaningfully improved these numbers since 2020.

NYHA classification describes how much a patient's symptoms limit physical activity: Class I is no limitation; Class II is slight limitation with ordinary activity; Class III is marked limitation; Class IV is symptoms at rest. It is the most widely used functional measure in HF clinical trials and is one of the strongest predictors of short-term mortality.

Both carry serious mortality risk. HFpEF has similar all-cause mortality to HFrEF, though HFrEF responds more reliably to established therapies (ACE inhibitors, beta-blockers, MRAs). HFpEF management has fewer proven disease-modifying treatments, though SGLT2 inhibitors now show benefit in both phenotypes.

APA

TG we-Calculate Editorial Team. (2026). Heart Failure Life Expectancy Calculator [Online calculator]. TG we-Calculate. https://we-calculate.com/calculator/heart-failure-life-expectancy-calculator

Chicago

TG we-Calculate Editorial Team. "Heart Failure Life Expectancy Calculator." TG we-Calculate. 2026. https://we-calculate.com/calculator/heart-failure-life-expectancy-calculator.

IEEE

TG we-Calculate Editorial Team, "Heart Failure Life Expectancy Calculator," TG we-Calculate, 2026. [Online]. Available: https://we-calculate.com/calculator/heart-failure-life-expectancy-calculator

BibTeX

@misc{wecalculate_heart_failure_life_expectancy_calculator, title = {Heart Failure Life Expectancy Calculator}, author = {{TG we-Calculate Editorial Team}}, howpublished = {\url{https://we-calculate.com/calculator/heart-failure-life-expectancy-calculator}}, year = {2026}, note = {TG we-Calculate} }

Did this calculator help you?